Modeling and Control of Drug Delivery Systems - Tapa blanda

Acerca del autor

Ahmad Azar is a Research Associate Professor at the Prince Sultan University, Riyadh, Kingdom Saudi Arabia. He is also an associate professor at the Faculty of Computers and Artificial intelligence, in Benha University, Egypt. He is the Editor in Chief of the International Journal of System Dynamics Applications (IJSDA), International Journal of Service Science, Management, Engineering, and Technology (IJSSMET), and International Journal of Intelligent Engineering Informatics (IJIEI), among others. He is currently Associate Editor of ISA Transactions, Elsevier, and the IEEE systems journal. Dr. Azar works in the areas of control theory & applications, process control, chaos control and synchronization, nonlinear control, renewable energy, computational intelligence.

De la contraportada

Various drug delivery and targeting systems have been developed to minimize drug degradation and adverse effect, and to increase drug bioavailability. Site-specific drug delivery may be either an active and/or passive process. Improving delivery techniques that minimize toxicity and increase efficacy offer significant potential benefits to patients and open up new markets for pharmaceutical companies.

Modeling and Control of Drug Delivery Systems provides comprehensive coverage of various drug delivery and targeting systems and their state-of-the-art related works, ranging from theory to real-world deployment. Also, it discusses the future perspectives of DDS.

This book will attract many researchers working in DDS field. This book will be an essential source of information for pharmaceutical scientists and pharmacologists working in academia as well as in the industry. It has useful information for pharmaceutical physicians and scientists in many disciplines involved in developing DDS such as chemical engineering, biomedical engineering, protein engineering, gene therapy. This will be an essential reference for executives in charge of research and development at several hundred companies that are developing drug delivery technologies.